Jackson Walker successfully represented ThermiGen, LLC, a medical technology company, in its sale to Almirall, S.A., a global pharmaceutical company, for approximately $75 million. The closing of the sale occurred in February 2016, which followed Almirall’s acquisition in September 2015 of a minority stake in ThermiGen for $5 million along with the payment of $2.5 million for a call option to acquire 100 percent of ThermiGen.
ThermiGen is a leading developer and manufacturer of thermistor-regulated energy systems for plastic surgery and dermatology applications. ThermiGen is focused on the worldwide distribution of its products, which products are based on the science of heat, using SmartTip technology to enable cosmetic physicians to use temperature as an endpoint.
ThermiGen was represented by a Jackson Walker team led by Rick Dahlson with assistance from Pete Hyndman. The successful transaction demonstrates the strength of Jackson Walker’s Corporate & Securities practice, which has extensive experience representing clients involved in all types of mergers and acquisitions, and a deep understanding of the unique challenges and sophisticated needs of clients in the healthcare industry.